AGLE 20.09 (+4.09%)
US00773J1034BiotechnologyBiotechnology

Aeglea BioTherapeutics (AGLE) Financial Metrics

This table shows a selected set of financial data points of Aeglea BioTherapeutics (AGLE). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2022 -0.99 0 -0.45 37.93M -0.93 2.33M -80.18M -84.78M -83.82M 34.86M
2021 -1.23 0 -3.85 253.52M -0.48 18.74M -54.29M -65.65M -65.8M 15.14M
2020 -1.52 0 -5.19 420.04M -0.66 21.84K -80.06M -80.49M -80.89M 90.1M
2019 -2.45 0 -3.12 244.1M -0.97 0 -67.18M -80.33M -78.25M 19.25M
2018 -2.13 0 -3.52 155.96M -0.66 3.89M -32.62M -44.06M -44.35M 22.46M
2017 -1.8 0 -3.01 81.84M -0.44 5.21M -25.23M -26.99M -27.24M 12.82M
2016 -2.22 0 -1.96 42.59M -0.41 4.63M -19.05M -21.57M -21.7M 47.75M
2015 -1.66 0 0 0 -0.54 6.09M -11.19M -11.21M -11.3M 29.29M
2014 -1.52 0 0 0 -2.75 0 -7.52M -10.33M -10.35M 2.62M
2013 0 0 0 0 0 0 0 0 0 4.6M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.